Biotech entity
CRISPR Therapeutics is most often covered alongside Vertex Pharmaceuticals, which appears in 2 of these 3 stories. Source depth averages 8 original sources per story, versus 3.5 across the same-window beat baseline. gene-therapy accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder.
Last mentioned: Jul 9, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 67 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
CRISPR Therapeutics is most often covered alongside Vertex Pharmaceuticals, which appears in 2 of these 3 stories. Source depth averages 8 original sources per story, versus 3.5 across the same-window beat baseline. gene-therapy accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. Across a 134-day span, the pace is roughly 0.2 stories per week. Their average consequence score of 7 runs above the beat's 6.1 for that window. CRISPR Therapeutics appears in 3 tracked Biotech stories published from February 26, 2026 through July 9, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 430 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering CRISPR Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Cure Announcement
Medical officials formally announce the patient is cured, marking a global first for gene editing technology.
Six-Month Follow-up
Clinical evaluations confirm significant biological markers of recovery and the absence of off-target effects.
Therapy Administration
A one-time gene editing intervention is administered at a specialized pediatric facility in British Columbia.
Trial Enrollment
The B.C. teen is enrolled in a world-first experimental gene editing clinical trial for a rare genetic disorder.
The FDA's expansion of Casgevy to children aged 2–11 solidifies Vertex and CRISPR Therapeutics' lead over bluebird bio’s Lyfgenia, opens a lucrative new patient segment, and validates the safety of CRISPR gene editing in very young patients.
Source: wdov.iheart.com · kogo.iheart.com
ARK Invest, led by Cathie Wood, has significantly increased its position in CRISPR Therapeutics (CRSP), signaling continued high conviction in the gene-editing pioneer despite recent market fluctuations. This move highlights Wood's strategy of doubling down on disruptive genomic technologies during periods of valuation compression.
Source: seekingalpha.com · Seeking Alpha
A British Columbia teenager has achieved a historic medical milestone, becoming the first person globally to be cured of a rare genetic disease using advanced gene editing technology. This breakthrough marks a definitive shift in the treatment of rare disorders, moving from chronic management to a potential one-time curative intervention.
Source: theprovince.com · theprovince.com
CRISPR Therapeutics is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
